- The FDA grants Rare Pediatric Disease (RPD) designation to Anavex Life Sciences' (NASDAQ:AVXL) lead drug Anavex 2-73 (blarcamesine) for the treatment of a rare inherited neurological disorder called Rett syndrome that affects mostly girls.
- RPD Designation provides for the issuance of a rare pediatric disease priority review voucher following FDA approval. The voucher can be used for accelerated approval of a future application or it can be sold to a third party.
- Phase 2 studies are in process.
- Shares up 7% premarket on light volume.
FDA grants RPD status to Anavex 2-73; shares ahead 7% premarket
Recommended For You
About AVXL Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
AVXL | - | - |
Anavex Life Sciences Corp. |